^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CART-BCMA/CS1

i
Other names: CART-BCMA/CS1
Associations
Trials
Company:
UCLA Jonsson Comprehensive Cancer Center
Drug class:
BCMA-targeted CAR-T immunotherapy, CS-1-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
7ms
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=0, Withdrawn, Jonsson Comprehensive Cancer Center | N=30 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal • IO biomarker
|
CD38 positive
|
cyclophosphamide • fludarabine IV • CART-BCMA/CS1
12ms
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Dec 2027 --> Mar 2028 | Initiation date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2026 --> Mar 2027
Trial completion date • Trial initiation date • Trial primary completion date • IO biomarker
|
CD38 positive
|
cyclophosphamide • fludarabine IV • CART-BCMA/CS1
over1year
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Jonsson Comprehensive Cancer Center
New P1 trial • IO biomarker
|
CD38 positive
|
cyclophosphamide • fludarabine IV • CART-BCMA/CS1